Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Revel Pharmaceuticals has developed a proprietary enzyme engineering platform to create designer enzymes that break down glucosepane crosslinks in collagen—a root cause of tissue stiffening and multiple age-related diseases. The company’s lead programs are preclinical but have demonstrated the ability to degrade these advanced glycation end-products in vitro and in animal models. The approach aims to reverse or repair molecular damage associated with aging, potentially restoring tissue function across several chronic conditions[6][7][8].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Revel Entertainment.